- Home
- AACG vs ACRV Comparison
AACG vs ACRV Comparison
Compare AACG & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- ACRV
- Stock Information
- Founded
- AACG 1999
- ACRV 2018
- Country
- AACG China
- ACRV United States
- Employees
- AACG N/A
- ACRV N/A
- Industry
- AACG Other Consumer Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- AACG Real Estate
- ACRV Health Care
- Exchange
- AACG Nasdaq
- ACRV Nasdaq
- Market Cap
- AACG 51.9M
- ACRV 47.8M
- IPO Year
- AACG N/A
- ACRV 2022
- Fundamental
- Price
- AACG $1.31
- ACRV $1.89
- Analyst Decision
- AACG
- ACRV Buy
- Analyst Count
- AACG 0
- ACRV 6
- Target Price
- AACG N/A
- ACRV $17.75
- AVG Volume (30 Days)
- AACG 58.0K
- ACRV 424.4K
- Earning Date
- AACG 11-10-2025
- ACRV 11-07-2025
- Dividend Yield
- AACG N/A
- ACRV N/A
- EPS Growth
- AACG N/A
- ACRV N/A
- EPS
- AACG N/A
- ACRV N/A
- Revenue
- AACG $39,064,701.00
- ACRV N/A
- Revenue This Year
- AACG N/A
- ACRV N/A
- Revenue Next Year
- AACG N/A
- ACRV $805.34
- P/E Ratio
- AACG N/A
- ACRV N/A
- Revenue Growth
- AACG 15.19
- ACRV N/A
- 52 Week Low
- AACG $0.70
- ACRV $1.05
- 52 Week High
- AACG $2.58
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- AACG 43.09
- ACRV 51.86
- Support Level
- AACG $1.15
- ACRV $1.92
- Resistance Level
- AACG $1.38
- ACRV $2.18
- Average True Range (ATR)
- AACG 0.14
- ACRV 0.15
- MACD
- AACG 0.03
- ACRV -0.01
- Stochastic Oscillator
- AACG 56.82
- ACRV 41.84
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.